5 Value Stocks To Watch In The Healthcare Sector
Portfolio Pulse from Benzinga Insights
The article lists 5 value stocks in the healthcare sector, selected by Benzinga Insights based on their low price-to-earnings (P/E) multiples, suggesting potential undervaluation. The stocks include Syros Pharmaceuticals (SYRS), BioNTech (BNTX), Cross Country Healthcare (CCRN), Solid Biosciences (SLDB), and Panbela Therapeutics (PBLA). The article provides recent earnings per share (EPS) data for these companies, indicating their financial performance in the most recent quarter compared to the previous one.
January 01, 2024 | 2:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioNTech, with a P/E of 8.44, showed an improvement in Q3 EPS at $0.73, up from -$0.86 in Q2.
The significant improvement in EPS is a positive development that could lead to a short-term increase in the stock price, reflecting the company's better-than-expected financial health.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Panbela Therapeutics has a P/E of 0.0 and reported a Q3 EPS of $-2.42, an improvement from $-7.95 in Q2.
Despite a P/E of 0.0, the significant improvement in EPS could attract investor interest, potentially increasing the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Solid Biosciences reported a P/E of 0.09 and an increase in Q3 EPS to $-1.05, a 16% improvement from Q2.
The increase in EPS could be a positive indicator for investors, potentially leading to a short-term uptick in the stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Cross Country Healthcare has a P/E of 8.01 with a decrease in Q3 EPS to $0.39 from $0.69 in Q2.
The drop in EPS could be viewed unfavorably by investors, potentially leading to a short-term decline in the stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Syros Pharmaceuticals has a low P/E of 8.47 but reported a 10% decrease in EPS in Q3 compared to Q2.
The decrease in EPS could be a negative signal to investors, potentially impacting the stock price negatively in the short term despite the low P/E ratio.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80